We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+8.27%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$21.8B
AUM Growth
+$3.36B
Cap. Flow
+$2.78B
Cap. Flow %
12.74%
Top 10 Hldgs %
12.04%
Holding
3,109
New
1,280
Increased
559
Reduced
519
Closed
699

Sector Composition

Rank Sector Weight
1 Healthcare 20.03%
2 Consumer Discretionary 13.15%
3 Technology 10.68%
4 Financials 9.81%
5 Communication Services 8.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GTYH
1901
DELISTED
GTY Technology Holdings, Inc. Common Stock
GTYH
$536K ﹤0.01%
+83,895
New +$590K
ZS icon
1902
Zscaler
ZS
$24.5B
$535K ﹤0.01%
3,116
-98,351
-97% -$19.5M
NEXT icon
1903
NextDecade
NEXT
$1.63B
$534K ﹤0.01%
+199,817
New +$444K
RDUS
1904
DELISTED
Radius Health, Inc.
RDUS
$534K ﹤0.01%
+25,569
New +$539K
ACTG icon
1905
Acacia Research
ACTG
$447M
$533K ﹤0.01%
+80,047
New +$504K
IPAR icon
1906
Interparfums
IPAR
$4.09B
$533K ﹤0.01%
+7,520
New +$510K
LSF icon
1907
Laird Superfood
LSF
$46.8M
$532K ﹤0.01%
+14,198
New +$604K
EWA icon
1908
iShares MSCI Australia ETF
EWA
$1.39B
$531K ﹤0.01%
+21,401
New +$532K
QUMU
1909
DELISTED
Qumu Corp.
QUMU
$531K ﹤0.01%
+78,593
New +$653K
APR
1910
DELISTED
Apria, Inc. Common Stock
APR
$530K ﹤0.01%
+18,999
New +$429K
PNTG icon
1911
Pennant Group
PNTG
$1.46B
$526K ﹤0.01%
+11,474
New +$632K
TXT icon
1912
Textron
TXT
$15.6B
$524K ﹤0.01%
+9,357
New +$474K
TFIN icon
1913
Triumph Financial Inc
TFIN
$1.84B
$523K ﹤0.01%
+6,761
New +$470K
GSAH.WS
1914
CALL
DELISTED
GS Acquisition Holdings Corp II Redeemable Warrants, each whole warrant exercisable for one share of
GSAH.WS
$522K ﹤0.01%
49,994
CVI icon
1915
CVR Energy
CVI
$3.39B
$518K ﹤0.01%
+27,041
New +$550K
EFA icon
1916
iShares MSCI EAFE ETF
EFA
$76.8B
$517K ﹤0.01%
+6,816
New +$513K
TLSA icon
1917
Tiziana Life Sciences
TLSA
$123M
$517K ﹤0.01%
+186,471
New +$619K
AI icon
1918
C3.ai
AI
$1.38B
$516K ﹤0.01%
7,834
-1,860
-19% -$216K
CTAS icon
1919
Cintas
CTAS
$86B
$516K ﹤0.01%
6,048
-70,820
-92% -$5.99M
HRMY icon
1920
Harmony Biosciences
HRMY
$2.07B
$514K ﹤0.01%
+15,545
New +$545K
BPFH
1921
DELISTED
Boston Private Financial Holdings, Inc.
BPFH
$514K ﹤0.01%
+38,624
New +$515K
EDU icon
1922
New Oriental
EDU
$8.08B
$513K ﹤0.01%
3,665
-62,427
-94% -$10.9M
SPFR.WS
1923
CALL
DELISTED
Jaws Spitfire Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one Cl
SPFR.WS
$512K ﹤0.01%
+49,990
New +$124K
HBB icon
1924
Hamilton Beach Brands
HBB
$323M
$508K ﹤0.01%
28,032
+16,565
+144% +$301K
OSK icon
1925
Oshkosh
OSK
$9.51B
$507K ﹤0.01%
4,272
+1,688
+65% +$175K

Similar funds

Marshall Wace's Q1 2021 Portfolio in Review

As of Q1 2021, Marshall Wace held 3,109 positions worth $21.8B, up 18% from $18.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Marshall Wace deployed $2.78B of net new capital in Q1 2021, opening 1,280 new positions and adding to 559 existing holdings. Its largest new stake was Paramount Global Class B: 5,936,494 shares worth $268M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 28% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $204M trimmed.

  • Marshall Wace's largest Q1 2021 buy was Paramount Global Class B: 5,936,494 shares worth $268M.
  • Marshall Wace added most to Farfetch Limited Class A Ordinary Shares in Q1 2021, an estimated $182M increase.
  • Marshall Wace's biggest Q1 2021 reduction was Thermo Fisher Scientific, cutting an estimated $204M.
  • Marshall Wace fully exited Vanguard Intermediate-Term Corporate Bond ETF in Q1 2021, selling an estimated $76.2M.
  • Marshall Wace's ten largest holdings make up 12% of its $21.8B portfolio in Q1 2021.
  • Marshall Wace opened 1,280 new positions and closed 699 in Q1 2021.
  • Marshall Wace's portfolio value rose 18% quarter-over-quarter to $21.8B.

Based on Marshall Wace's 13F filing for Q1 2021, filed 17 May 2021.